Since 2015, Dr. Toren has worked as a clinician-scientist in the Department of Surgery at Laval University, where his laboratory focuses on translational prostate cancer research. He completed his medical training at Queen’s University in Kingston, Ontario, urology residency and a clinical uro-oncology fellowship at the University of Toronto. Subsequently, he completed a two-year research fellowship at the Vancouver Prostate Centre, under the mentorship of Dr. Martin Gleave. Concurrently, he enrolled in, and recently completed a doctorate in experimental medicine in Dr. Amina Zoubeidi’s laboratory.
The influence of sex steroids on the tumor environment
Androgens and estrogens are important to prostate cancer progression and treatment resistance. Through the analysis of various sex steroids such as testosterone and estrogens, we seek to better understand the hormonal changes which occur following treatment in prostate cancer patients. Further, we seek to understand how differences in these levels between patients may be used to classify them for optimal treatments and understand resistance patterns. We use laboratory models to understand the effect of sex steroids on the local immune environment and production of cytokines regulating the survival and growth of prostate cancer.
Extracellular vesicles as biomarkers
Extracellular vesicles, such as exosomes, are tiny parts of cells which may be detected in many biological fluids, including urine and blood. Using samples from prostate cancer patients, we seek to optimize isolation, enumeration, and characterization techniques. Versatile and containing a significant amount of information pertinent to cancer type and function, these tiny particles may eventually be used to monitor information about responsiveness to treatments through a simple blood test.
6, rue McMahon
Canada G1R 2J6
- Berrehail, ZohraDoctoral firstname.lastname@example.org
- Boibessot, ClovisDoctoral studentL'Hôtel-Dieu de Québec+1 418-525-4444, extension email@example.com@crchudequebec.ulaval.ca
10, rue McMahon
Canada G1R 3S3
- Gilbert, SophieEmployeesophie.firstname.lastname@example.org
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.Journal Article
J Clin Oncol, 33 (10), pp. 1151-6, 2015, ISSN: 0732-183X.
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.Journal Article
Mol Cancer Ther, 14 (1), pp. 59-69, 2015, ISSN: 1535-7163.
Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).Journal Article
Int J Oncol, 45 (5), pp. 1793-801, 2014, ISSN: 1019-6439.
Active surveillance in patients with a PSA >10 ng/mL.Journal Article
Can Urol Assoc J, 8 (9-10), pp. E702-7, 2014, ISSN: 1911-6470.
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.Journal Article
Oncogenesis, 3 , pp. e115, 2014, ISSN: 2157-9024.
Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment.Journal Article
Clin Genitourin Cancer, 12 (1), pp. 21-6, 2014, ISSN: 1558-7673.
Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study.Journal Article
Can Urol Assoc J, 7 (11-12), pp. E692-8, 2013, ISSN: 1911-6470.
Novel non-AR therapeutic targets in castrate resistant prostate cancer.Journal Article
Transl Androl Urol, 2 (3), pp. 265-77, 2013, ISSN: 2223-4683.
Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus.Journal Article
Urology, 82 (3), pp. 572-7, 2013, ISSN: 0090-4295.
Rational cotargeting of Pim-1 and Akt in prostate cancer.Journal Article
Expert Rev Anticancer Ther, 13 (8), pp. 937-9, 2013, ISSN: 1473-7140.
- (FRSQ 91289) Androgen-receptor dependent changes in human bladder cancer macrophages.” , Subvention, Northeastern Section of the American Urological Association, from 2019-09-04 to 2021-09-03
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
- Development of next-generation biomarkers for prostate cancer treatment, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2019-07-01 to 2020-12-31
- Sex steroids as modulators of the prostate cancer immune microenvironment, Subvention, Société de recherche sur le cancer, Subvention de fonctionnement, from 2018-09-01 to 2021-08-31
Recently finished projects
- Enhancing bladder cancer immunotherapy efficacy in men using bicalutamide, Subvention, Société de recherche sur le cancer, from 2018-12-01 to 2019-11-30
- Investiguer les facteurs moléculaires qui influencent la progression du cancer de la prostate, Subvention, Clinique d'urologie Berger S.E.N.C., from 2016-03-31 to 2019-06-30
- Investiguer les facteurs moléculaires qui influencent la progression du cancer de la prostate., Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2016-07-01 to 2020-06-30
- Investiguer les facteurs moléculaires qui influencent la progression du cancer de la prostate., Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2016-07-01 to 2019-06-30